There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Greenbrook Tms (GBNH) with bullish sentiments.
Greenbrook Tms (GBNH)
Bloom Burton analyst David Martin PhD maintained a Buy rating on Greenbrook Tms on April 1 and set a price target of $16.00. The company’s shares closed last Thursday at $12.65.
According to TipRanks.com, PhD is a 5-star analyst with an average return of 30.9% and a 47.5% success rate. PhD covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, ESSA Pharma, and Zymeworks.
Greenbrook Tms has an analyst consensus of Strong Buy, with a price target consensus of $18.86, implying a 49.5% upside from current levels. In a report issued on March 25, Stifel Nicolaus also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
